Two-gene expression ratio as predictor for breast cancer treated with tamoxifen: evidence from meta-analysis
- 225 Downloads
A HOXB13-to-IL17BR expression ratio was previously identified to predict a clinical outcome of breast cancer patients treated with adjuvant tamoxifen. A large number of studies were addressed to confirm its function as a predictor of breast cancer outcome treated with tamoxifen. However, conflicting results were got. In this study, a systematic search of databases was carried out, and other relevant papers were also identified. Then, the analyses were conducted according to the PRISMA and MOOSE guidelines. After full review, 11 studies with a total of 2,958 participants were deemed eligible and were included in the study. Pooled results revealed that women with higher HOXB13-to-IL17BR expression ratio had significantly worse outcomes in breast patients treated with tamoxifen, especially for those who are negative of node.
KeywordsHOXB13 IL17BR Meta-analysis Breast cancer Tamoxifen
The work was supported by the Key Project of Science and Technology, Tianjin Municipal Science and Technology Commission (grant no. 11ZCGYSY02200). The authors thank all of the authors of primary studies included in their meta-analyses.
Conflicts of interest